Production (Stage)
RAMM Pharma Corp.
RAMM
CNSX
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -14.72% | -4.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.72% | -4.97% | |||
| Cost of Revenue | -9.88% | 51.30% | |||
| Gross Profit | -31.80% | -58.92% | |||
| SG&A Expenses | -31.32% | -72.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 40.54% | -94.83% | |||
| Total Operating Expenses | -23.58% | -62.28% | |||
| Operating Income | 30.92% | 74.84% | |||
| Income Before Tax | 89.79% | 90.69% | |||
| Income Tax Expenses | 205.10% | -1,164.41% | |||
| Earnings from Continuing Operations | 79.72% | 91.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 79.72% | 91.44% | |||
| EBIT | 30.92% | 74.84% | |||
| EBITDA | 35.74% | 77.61% | |||
| EPS Basic | 80.00% | 91.48% | |||
| Normalized Basic EPS | 43.90% | 77.09% | |||
| EPS Diluted | 80.00% | 91.48% | |||
| Normalized Diluted EPS | 43.90% | 77.09% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||